Aripiprazole Tablet
Product Images NDC 65162-902

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 65162-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

Chemical structure diagram of aripiprazole, illustrating its molecular configuration including chloro-substituted aromatic rings and heterocyclic components, consistent with the active ingredient aripiprazole.*

FDA Label Image

2 mg Label (Aripiprazole Tablets 10)

Label for Aripiprazole Tablets USP, 2 mg oral tablets by Amneal Pharmaceuticals LLC. The label states 'Rx only' and indicates a package size of 30 tablets. Storage instructions and manufacturer/distributor information are included, along with a QR code and barcode.*

FDA Label Image

5 mg Label (Aripiprazole Tablets 11)

Label for Aripiprazole 5 mg tablets, USP by Amneal Pharmaceuticals LLC. The label includes the NDC number 65162-897-03 and states the package contains 30 tablets. It features a blue elliptical tablet imprint with 'AN897' and '5'. Storage instructions specify 20° to 25°C with allowed excursions, and it includes manufacturing details from Amneal Pharmaceuticals Pvt. Ltd. in India and distribution details in New Jersey.*

FDA Label Image

10 mg Label (Aripiprazole Tablets 12)

Label for Aripiprazole Tablets USP 10 mg by Amneal Pharmaceuticals LLC. The label indicates a bottle containing 30 oral tablets. The label includes storage instructions, manufacturing and distribution details, a medication guide reference with a QR code, and the NDC number 65162-898-03.*

FDA Label Image

15 mg Label (Aripiprazole Tablets 13)

Aripiprazole Tablets, USP 15 mg packaging label from Amneal Pharmaceuticals LLC. The label states this is an oral tablet dosage form with 30 tablets per container and notes it is prescription only (Rx only). Storage instructions and manufacturer information are also included.*

FDA Label Image

20 mg Label (Aripiprazole Tablets 14)

Label for Aripiprazole Tablets USP 20 mg oral tablets by Amneal Pharmaceuticals LLC. The label indicates a carton containing 30 tablets, with storage instructions and manufacturer information for Amneal Pharmaceuticals Pvt. Ltd. in India and distribution by Amneal Pharmaceuticals LLC in New Jersey, USA.*

FDA Label Image

30 mg Label (Aripiprazole Tablets 15)

Label for Aripiprazole Tablets USP 30 mg, oral tablets supplied by Amneal Pharmaceuticals LLC. The label indicates a package containing 30 tablets with a prescription-only designation. It includes storage instructions, a QR code for the Medication Guide, and manufacturer and distributor information from Amneal Pharmaceuticals Pvt. Ltd. and Amneal Pharmaceuticals LLC.*

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

A horizontal error bar chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for Aripiprazole pharmacokinetics (AUC and Cmax) when coadministered with various drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The x-axis represents change relative to reference without interacting drug.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing Dehydro-Aripiprazole fold change and 90% confidence intervals. It compares the effects of various CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs on aripiprazole exposure (AUC and Cmax) relative to a reference without interacting drugs.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

A forest plot illustrating the effect of Aripiprazole on the pharmacokinetics (PK) of various drugs, including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis shows fold change and 90% confidence interval relative to reference (without interacting drug), with data points for AUC and Cmax values.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

A pharmacokinetic (PK) chart showing Aripiprazole fold change and 90% confidence intervals for different special populations. Variables compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The chart plots changes in AUC and Cmax relative to a reference value of 1.0 on the x-axis.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

A pharmacokinetic (PK) chart showing fold changes and 90% confidence intervals in Dehydro-Aripiprazole exposure (AUC and Cmax) relative to reference values. Comparisons include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment.*

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

A Kaplan-Meier relapse curve chart showing proportion with relapse over days from randomization for Aripiprazole and placebo groups. The x-axis represents time in days up to 182, and the y-axis shows the proportion with relapse up to 1.0. The graph includes numbers of subjects at risk at various time points for both groups, with Aripiprazole in a solid blue line and placebo in a dashed red line.*

FDA Label Image

01 (Aripiprazole Tablets 8)

A Kaplan-Meier curve graph showing the proportion of subjects with relapse over 182 days from randomization for Aripiprazole and Placebo groups. The X-axis represents days from randomization, and the Y-axis shows the proportion with relapse. The graph includes a table with the number of subjects at risk in each group across different time points.*

FDA Label Image

0102 (Aripiprazole Tablets 9)

Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization up to 364 days, with the number of subjects at risk noted below. The y-axis shows the proportion with relapse ranging from 0 to 1. The Aripiprazole group line is solid, and the placebo group line is dashed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.